drugset
drugset / Trial / NCT03826875

Poststroke Depression in Hemorrhagic Stroke

NCT03826875 ↗

Phase 2 Completed 8 enrolled University of Washington
RandomizedParallel-groupTriple-blindPrevention

Summary

A double-blinded placebo-controlled randomized trial to evaluate the effect of preventative treatment of depression in survivors of aneurysmal subarachnoid hemorrhage (aSAH), a type of stroke.

Timeline

Start
2019-03-01
Primary completion
2025-05-07
Completion
2025-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 20 mg Oral

Indications

depressive disorder hemorrhagic stroke